Shed's structure is refreshingly readable: $299 on the 1-month plan, and the price stays the same as your dose goes up. Health coaching, dietitian support and a member community are listed as part of the plan. There is nothing to decode, which is more than several options here manage.
The detail that matters most is the commitment. The 6- and 12-month plans cost less per month but come with minimum-term rules, and Shed's own terms also mention a two-month minimum on monthly subscriptions.
Here is how Shed reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
What Shed’s published price covers, taken from its own pages and checked October 2026. “Not listed on their site” means we could not find it published.
Tirzepatide is titrated upward over months, and with many providers the bill climbs as the dose does. Shed publishes one figure that holds as the dose rises, so the cost you start with is the cost you plan around. That is the main thing it does well, and it is set out on its own pages rather than left for checkout.
Longer plans are cheaper per month, and cancelling follows the provider's published policy: in the portal at least 72 hours before billing, with no refunds once a charge has gone through. Those facts deserve to be weighed together. Committing several months ahead before you know how you respond is a specific risk, so read both terms in one sitting before choosing a plan length.
Put these to Shed in writing, and keep the reply.
Shed rates low here because the Charter's whole-person rows are not addressed on its pages. If you want one flat price that holds as the dose rises, with coaching and community included, it is clear and straightforward. Settle the commitment question first.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.